Opinion|Videos|July 16, 2024
Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.
Advertisement
Episodes in this series
- How redefining SCLC as a molecularly heterogeneous malignancy might better inform personalized treatment of its subtypes with unique therapeutic vulnerabilities.
- How the mechanism of promoter methylation levels in ctDNA subtypes contribute to “subtype switching” in relapsed SCLC.
- Potential contribution of subtype switching to treatment resistance (platinum-based chemotherapy)
- How ‘switching’ to an inflammatory phenotype might improve therapeutic response to immune checkpoint inhibitors vs other SCLC subtypes
- The variable response of SCLC subtypes to currently available therapies
- Briefly discuss significant adverse events in patients with LS-SCLC who receiveIO-based regimens and explore strategies for their mitigation and management.
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5